459 related articles for article (PubMed ID: 26385871)
1. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
Rajendran R; Grossman AB; Kar P
Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
[TBL] [Abstract][Full Text] [Related]
3. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
5. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
[TBL] [Abstract][Full Text] [Related]
7. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Pose-Reino A; Runkle de la Vega I; de Jong-Laird A; Kabra M; Lindner U
Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
[TBL] [Abstract][Full Text] [Related]
8. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
Estilo A; McCormick L; Rahman M
Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
[TBL] [Abstract][Full Text] [Related]
9. Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.
Chatzimavridou-Grigoriadou V; Al-Othman S; Brabant G; Kyriacou A; King J; Blackhall F; Trainer PJ; Higham CE
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4766-e4775. PubMed ID: 33693944
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
12. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
Tzoulis P; Carr H; Bagkeris E; Bouloux PM
Endocrine; 2017 Feb; 55(2):539-546. PubMed ID: 27837439
[TBL] [Abstract][Full Text] [Related]
13. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
14. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
[TBL] [Abstract][Full Text] [Related]
15. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
16. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
Harbeck B; Lindner U; Haas CS
Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
[No Abstract] [Full Text] [Related]
17. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
[TBL] [Abstract][Full Text] [Related]
18. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
Shoaf SE; Bricmont P; Dandurand A
Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]